DELRAY BEACH, Fla., Sept. 1, 2025 /PRNewswire/ -- The global Contract Research Organization Services Market, valued at US$79.10 billion in...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS...
Black Book Flash Survey of VCs, PEs, Bankers, Analysts and Influencers Reveals Q4's Hottest Healthcare Investment NEW YORK CITY, NY...
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded...
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis...
Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been...
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American...
DALLAS, Aug. 31, 2025 /PRNewswire/ -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the...
Largest Health Systems AI 2025 comprehensive survey to date highlights adoption momentum and governance gap in U.S. hospitals CHICAGO, IL...
After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control...
Why Weight Loss Feels Impossible After 35 NEW YORK CITY, NY / ACCESS Newswire / August 31, 2025 / For...
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE...
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the...
MIAMI, FL / ACCESS Newswire / August 30, 2025 / In today's fast-paced world, maintaining mental sharpness, focus, and memory...
MIAMI BEACH, FLORIDA / ACCESS Newswire / August 30, 2025 / Nutriessential, a U.S.-based professional-grade dietary supplement provider, proudly announces...
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or...
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting...
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to...
VANCOUVER, BC / ACCESS Newswire / August 29, 2025 / GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company"), a...